Výsledky vyhledávání

Akademický článek

Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1 ⁺ Activated T Cells.

Autor: Dovedi SJ; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom. simon.dovedi@astrazeneca.com yariv.mazor@astrazeneca.com., Elder MJ; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Yang C; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Sitnikova SI; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Irving L; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Hansen A; Translational Science and Experimental Medicine, Respiratory and Immunology (RI), Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Hair J; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Jones DC; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Hasani S; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Wang B; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Im SA; Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University School of Medicine, Seoul, Korea., Tran B; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia., Subramaniam DS; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Gainer SD; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Vashisht K; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Lewis A; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Jin X; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Kentner S; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Mulgrew K; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Wang Y; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Overstreet MG; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Dodgson J; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Wu Y; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Palazon A; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Morrow M; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Rainey GJ; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Browne GJ; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Neal F; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Murray TV; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Toloczko AD; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Dall'Acqua W; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Achour I; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Freeman DJ; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Wilkinson RW; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Mazor Y; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland. simon.dovedi@astrazeneca.com yariv.mazor@astrazeneca.com.

Publikováno v: Cancer discovery [Cancer Discov] 2021 May; Vol. 11 (5), pp. 1100-1117. Date of Electronic Publication: 2021 Jan 08.

Zobrazit plný text záznamu

Akademický článek

Characterization of a Novel Bispecific Antibody With Improved Conformational and Chemical Stability.

Autor: Manikwar P; Dosage Form Design & Development, AstraZeneca, Gaithersburg, Maryland 20878. Electronic address: manikwarp@medimmune.com., Mulagapati SHR; Analytical Sciences, AstraZeneca, Gaithersburg, Maryland 20878., Kasturirangan S; Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland 20878., Moez K; Dosage Form Design & Development, AstraZeneca, Gaithersburg, Maryland 20878., Rainey GJ; Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland 20878., Lobo B; Dosage Form Design & Development, AstraZeneca, Gaithersburg, Maryland 20878.

Publikováno v: Journal of pharmaceutical sciences [J Pharm Sci] 2020 Jan; Vol. 109 (1), pp. 220-232. Date of Electronic Publication: 2019 Jul 06.

Zobrazit plný text záznamu

Akademický článek

Structure and biophysical characterization of the human full-length neurturin-GFRa2 complex: A role for heparan sulfate in signaling.

Autor: Sandmark J; From the Departments of Structure, Biophysics and Fragment-based Lead Generation, Discovery Sciences., Dahl G; From the Departments of Structure, Biophysics and Fragment-based Lead Generation, Discovery Sciences., Öster L; From the Departments of Structure, Biophysics and Fragment-based Lead Generation, Discovery Sciences., Xu B; the Division of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 17177, Sweden.; Discovery Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg 43183, Sweden., Johansson P; From the Departments of Structure, Biophysics and Fragment-based Lead Generation, Discovery Sciences., Akerud T; From the Departments of Structure, Biophysics and Fragment-based Lead Generation, Discovery Sciences., Aagaard A; From the Departments of Structure, Biophysics and Fragment-based Lead Generation, Discovery Sciences., Davidsson P; Bioscience, Cardiovascular and Metabolic Diseases, and., Bigalke JM; From the Departments of Structure, Biophysics and Fragment-based Lead Generation, Discovery Sciences., Winzell MS; Bioscience, Cardiovascular and Metabolic Diseases, and., Rainey GJ; the Department of Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland 20878, and., Roth RG; Discovery Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg 43183, Sweden, robert.roth@astrazeneca.com.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2018 Apr 13; Vol. 293 (15), pp. 5492-5508. Date of Electronic Publication: 2018 Feb 02.

Zobrazit plný text záznamu

Akademický článek

A neutralizing antibody that blocks delivery of the enzymatic cargo of Clostridium difficile toxin TcdB into host cells.

Autor: Kroh HK; From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2363., Chandrasekaran R; From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2363., Zhang Z; Department of Biochemistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada.; Molecular Structure and Function, The Hospital for Sick Children, Toronto, Ontario M5G 0A4, Canada., Rosenthal K; MedImmune LLC, Gaithersburg, Maryland 20878-2204., Woods R; MedImmune LLC, Gaithersburg, Maryland 20878-2204., Jin X; MedImmune LLC, Gaithersburg, Maryland 20878-2204., Nyborg AC; MedImmune LLC, Gaithersburg, Maryland 20878-2204., Rainey GJ; MedImmune LLC, Gaithersburg, Maryland 20878-2204., Warrener P; MedImmune LLC, Gaithersburg, Maryland 20878-2204., Melnyk RA; Department of Biochemistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada.; Molecular Structure and Function, The Hospital for Sick Children, Toronto, Ontario M5G 0A4, Canada., Spiller BW; From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2363.; Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232-6600, and., Lacy DB; From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2363, borden.lacy@vanderbilt.edu.; Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee 37212-2637.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2018 Jan 19; Vol. 293 (3), pp. 941-952. Date of Electronic Publication: 2017 Nov 27.

Zobrazit plný text záznamu

Akademický článek

Use of a neutralizing antibody helps identify structural features critical for binding of Clostridium difficile toxin TcdA to the host cell surface.

Autor: Kroh HK; From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2363., Chandrasekaran R; From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2363., Rosenthal K; MedImmune LLC, Gaithersburg, Maryland 20878-2204., Woods R; MedImmune LLC, Gaithersburg, Maryland 20878-2204., Jin X; MedImmune LLC, Gaithersburg, Maryland 20878-2204., Ohi MD; the Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee 37232-8240., Nyborg AC; MedImmune LLC, Gaithersburg, Maryland 20878-2204., Rainey GJ; MedImmune LLC, Gaithersburg, Maryland 20878-2204., Warrener P; MedImmune LLC, Gaithersburg, Maryland 20878-2204., Spiller BW; From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2363, benjamin.spiller@vanderbilt.edu.; the Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232-6600, and., Lacy DB; From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2363, borden.lacy@vanderbilt.edu.; the Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee 37212-2637.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2017 Sep 01; Vol. 292 (35), pp. 14401-14412. Date of Electronic Publication: 2017 Jul 13.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání